Doing it For the Kids
Pfizer aims to improve pediatric clinical trials with increased investment.
Maryam Mahdi | | Quick Read
Looking to improve medicines for children, Pfizer is investing £5 million in its Discovery Park site based in Kent, UK. Pfizer has a long-standing relationship with Kent County Council. “Since 1954, we have invested in manufacturing and advanced science capabilities. Our priority is to continue to ensure that the local area remains a hub of scientific excellence and a vibrant life science community,” says a Pfizer spokesperson.
Pediatric clinical trials can often be limited by the complexities associated with the demographic. Patients who fall into the category can be divided into several age groups, with each presenting different physiological characteristics with different pharmacokinetic and pharmacodynamic parameters. Dose flexibility and formulation, as well as poor patient compliance due to potential issues with taste-masking, can also hinder the success of trials.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.